Last update 31 May 2025

UTAA-91

Overview

Basic Info

Drug Type
γ-δT
Synonyms-
Target
CD19
Action
modulators
Mechanism
CD19 modulators(B-lymphocyte antigen CD19 modulators)
Therapeutic Areas
Immune System DiseasesNervous System DiseasesEye Diseases+ [3]
Active Indication
Idiopathic Inflammatory MyopathiesScleroderma, SystemicSjogren's Syndrome+ [1]
Inactive Indication-
Originator Organization
PersonGen BioTherapeutics (Suzhou) Co., Ltd.PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Active Organization
PersonGen BioTherapeutics (Suzhou) Co., Ltd.PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhaseEarly Phase 1
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with UTAA-91
NCT06982547
/ Not yet recruitingEarly Phase 1
Clinical Study on the Treatment of Refractory Moderate - to - Severe Active Rheumatoid Arthritis With UTAA91 Injection
NCT06982534
/ Not yet recruitingEarly Phase 1
Clinical Study on the Treatment of Refractory Moderate-to-Severe Active Systemic Sclerosis With UTAA91 Injection
NCT06970951
/ Not yet recruitingEarly Phase 1
A Single-Arm, Open-Label, Single-Center Investigator-Initiated Early-Stage Clinical Study for Relapsed/Refractory (R/R) Autoimmune Diseases
100 Clinical Results associated with UTAA-91
Login to view more data
100 Translational Medicine associated with UTAA-91
Login to view more data
100 Patents (Medical) associated with UTAA-91
Login to view more data
100 Deals associated with UTAA-91
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Idiopathic Inflammatory MyopathiesPhase 1
China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.PersonGen BioTherapeutics (Suzhou) Co., Ltd.
18 May 2025
Scleroderma, SystemicPhase 1
China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.PersonGen BioTherapeutics (Suzhou) Co., Ltd.
18 May 2025
Sjogren's SyndromePhase 1
China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.PersonGen BioTherapeutics (Suzhou) Co., Ltd.
18 May 2025
Systemic Lupus ErythematosusPhase 1
China
PersonGen BioTherapeutics (Suzhou) Co., Ltd.PersonGen BioTherapeutics (Suzhou) Co., Ltd.
18 May 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free